ADVERSE REACTIONS SECTION.


ADVERSE REACTIONS. Cardiovascular rapid pulse, flushing Central Nervous System blurred vision, dizziness Respiratory shortness of breath or troubled breathing Genitourinary difficulty micturition, acute urinary retention Gastrointestinal dry mouth, nausea/vomiting.

PEDIATRIC USE SECTION.


Pediatric. infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids.

PRECAUTIONS SECTION.


PRECAUTIONS. (Pregnancy Category C) hyoscyamine and methenamine cross the placenta. Studies have not been done in animals or humans. It is not known whether ME/NaPhos/MB/Hyo Tablets cause fetal harm when administered to pregnant woman or can affect reproduction capacity. ME/NaPhos/MB/Hyo Tablets should be given to pregnant woman only if clearly needed.

SPL UNCLASSIFIED SECTION.


Breast-feeding. problems in humans have not been documented; however, methenamine and traces of hyoscyamine are excreted in breast milk.

WARNINGS SECTION.


WARNINGS. Do not exceed recommended dosage. If rapid pulse, dizziness, or blurring of vision occurs discontinue use immediately.

CLINICAL PHARMACOLOGY SECTION.


CLINICAL PHARMACOLOGY. HYOSCYAMINE is parasympatholytic which relaxes smooth muscles and thus produces an antispasmodic effect. It is well absorbed from the gastrointestinal tract and is rapidly distributed throughout body tissues. Most is excreted in the urine within 12 hours, 13% to 50% being unchanged. Its biotransformation is hepatic. Its protein binding is moderate. METHENAMINE degrades in an acidic urine environment releasing formaldehyde which provides bactericidal or bacteriostatic action. It is well absorbed from the gastrointestinal tract. 70% to 90% reaches the urine unchanged at which point it is hydrolyzed if the urine is acidic. Within 24 hours it is almost completely (90%) excreted; of this amount at pH 5, approximately 20% is formaldehyde. Protein binding: some formaldehyde is bound to substances in the urine and surrounding tissues. Methenamine is freely distributed to body tissue and fluids but is not clinically significant as it does not hydrolyze at pH greater than 6.8. METHYLENE BLUE possesses weak antiseptic properties. It is well absorbed in the gastrointestinal tract and is rapidly reduced to leukomethylene blue which is stabilized in some combination form in the urine. 75% is excreted unchanged. MONOBASIC SODIUM PHOSPHATE helps to maintain an acid pH in the urine necessary for the degradation of methenamine.

DESCRIPTION SECTION.


Description. Each tablet contains:Methenamine, USP ................................. 81.6 mg Monobasic Sodium Phosphate, USP ......... 40.8 mg Methylene Blue ....................................... 10.8 mg Hyoscyamine Sulfate ............................... 0.12 mg.

DOSAGE & ADMINISTRATION SECTION.


DOSAGE AND ADMINISTRATION. AdultsOne tablet orally times per day followed by liberal fluid intake. Older ChildrenDosage must be individualized by physician. Not recommended for use in children up to years of age.

DRUG ABUSE AND DEPENDENCE SECTION.


DRUG ABUSE AND DEPENDENCE. dependence on the use of ME/NaPhos/MB/Hyo Tablets has not been reported and due to the nature of its ingredients, abuse of ME/NaPhos/MB/Hyo Tablets is not expected.

DRUG INTERACTIONS SECTION.


Drug Interactions. because of this products effect on gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications during concurrent use such as: urinary alkalizers; thiazide diuretics (may cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde); antimuscarinics (concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications); antacids/antidiarrheals (may reduce absorption of hyoscyamine, concurrent use with antacids may cause urine to become alkaline reducing effectiveness of methenamine by inhibiting its conversion to formaldehyde) doses of these medications should be spaced hour apart from doses of hyoscyamine; antimyasthenics (concurrent use with hyoscyamine may further reduce intestinal motility); ketoconazole (patients should be advised to take this combination at least hours after ketoconazole); monoamine oxidase (MAO) Inhibitors (concurrent use may intensify antimuscarinic side effects, opioid (narcotic) analgesics may result in increased risk of severe constipation); sulfonamides (these drugs may precipitate with formaldehyde in the urine, increasing the danger of crystalluria). Patients should be advised that the urine may become blue to blue green and the feces may be discolored as result of the excretion of methylene blue.

GENERAL PRECAUTIONS SECTION.


DIRECTIONS: Tablet times daily followed by liberal fluid intake, or as directed by physician. FOR FULL PRODUCT INFORMATION SEE ATTACHED BOOKLET.Store at 25 (77 F); excursions permitted to 15 to 30 (59 to 86 F) [See USP Controlled Room Temperature]. Protect from moisture or direct sunlight. NOTE: Patient should be advised that urine will be colored blue while taking this medication. PHARMACIST: Preserve and dispense in tight-light resistant container as defined in the USP. KEEP THIS AND ALL MEDICINES OUT OF THE REACH OFCHILDREN.Tamper evident by heat seal under cap. Do not use if there is evidence of tampering. To report an adverse event, please contact Method Pharmaceuticals, LLC at (877) 250-3427.

GERIATRIC USE SECTION.


Geriatric. use with caution in elderly patients as they may respond to usual doses of hyoscyamine with exctextent, agitation, drowsiness, or confusion.

HOW SUPPLIED SECTION.


HOW SUPPLIED. ME/NaPhos/MB/Hyo Tablets are light blue to blue, oval, biconvex tablets debossed with M455 with scoreline on one side and plain on the other side. Supplied in bottles of 100 tablets (NDC 58657-454-01).

INACTIVE INGREDIENT SECTION.


Inactive Ingredients include:. Microcrystalline Cellulose, Mannitol, Croscarmellose Sodium, Magnesium Stearate, FD&C Blue HYOSCYAMINE SULFATE is an alkaloid of belladonna. Exists as white crystalline powder. Affected by light It is very soluble in water; freely soluble in alcohol; practically insoluble in ether. METHENAMINE exists as colorless, lustrous crystals or white crystalline powder. Its solutions are alkaline to litmus. Freely soluble in water; soluble in alcohol and in chloroform. METHYLENE BLUE exists as dark green crystals. It is soluble in water and in chloroform; sparingly soluble in alcohol. MONOBASIC SODIUM PHOSPHATE exists as white crystalline powder. Its solutions are acidic to litmus. It is freely soluble in water and practically insoluble in alcohol. This product is not an Orange Book (OB) rated product, therefore all prescriptions using this product shall be pursuant to state statutes as applicable. There are no claims of bioequivalence or therapeutic equivalence.

INDICATIONS & USAGE SECTION.


INDICATION AND USAGE. ME/NaPhos/MB/Hyo Tablets is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.

OTHER SAFETY INFORMATION.


CAUTIONRX ONLY STORAGEStore at 25 (77 F); excursions permitted to 15 to 30 (59 to 86 F) [See USP Controlled Room Temperature]. Keep container tightly closed. Distributed By: Method Pharmaceuticals, LLC Arlington, TX 76006 Rev. Date: 01/2016.

OVERDOSAGE SECTION.


OVERDOSAGE. Emesis or gastric lavage. Slow intravenous administration of physostigmine in doses of mg to mg (0.5 mg to mg in children), repeated as needed in one to two hours to reverse severe antimuscarinic symptoms. Administration of small doses of diazepam to control exctextent and seizures. Artificial respiration with oxygen if needed for respiratory depression. Adequate hydration. Symptomatic treatment as necessary.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.


Distributed by: Method Pharmaceuticals, LLC Arlington, TX 76006 Rev. Date: 01/2016 Pinciple Display PanelBooklet. Principle Display. Booklet.